MedPath

Esperas Pharma Inc.

Esperas Pharma Inc. logo
🇨🇦Canada
Ownership
Holding
Established
2015-01-01
Employees
1
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:1

Trial Phases

1 Phases

Phase 1:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (100.0%)

A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

Phase 1
Completed
Conditions
Ovarian Cancer
Endometrial Cancer
Soft Tissue Sarcoma
Triple Negative Breast Cancer
Pancreas Cancer
Solid Tumors
Colorectal Cancer
Neoplasms
Breast Cancer
Colon Cancer
Interventions
First Posted Date
2015-12-16
Last Posted Date
2025-05-02
Lead Sponsor
Esperas Pharma Inc.
Target Recruit Count
229
Registration Number
NCT02632448
Locations
🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Karmanos Cancer Institute, Detroit, Michigan, United States

🇨🇦

Tom Baker Cancer Centre, Calgary, Alberta, Canada

and more 13 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.